- Details
- (Length of Discussion 21 min) Jeannette Potts presents the causes and treatments of nocturia. Nocturia, the most common lower urinary tract symptom is a condition in which a patient expereinces nighttime awakening to void. Nocturia affects approximately 70-75% of adults over 40 years of age. She reviews multiple symptoms causes by nocturnal polyuria including chronic fatigue, depression, hypertens...
|
- Details
- (Length of Conversation: 19 min) Mary-Ellen Taplin, MD, and Alicia Morgans, MD discuss the topic of neoadjuvant therapy for men with high-risk disease prior to surgery, specifically, prior to prostatectomy. Among the topics discussed include the importance of studying neoadjuvant chemotherapy and hormonal therapies in clinical trials before being used more broadly in everyday clinical practice, pa...
|
- Details
- (Length of Discussion: 15 min) Lawrence I Karsh discusses SpaceOAR Hydrogel and it's use as a prostate-rectum spacer for treating prostate cancer with radiation therapy. He presents a study he took part in which aimed to evaluate the safety of the prostate-rectum spacer application technique as well as the following: the implant quality and resulting rectal dose reduction, acute and long term rect...
|
- Details
- (Length of Discussion: 5 min) Dr. Thomas Keane discusses a group analysis of an online tool to explore evolving practice patterns among patients with renal cell carcinoma (RCC), a topic presented by Dr. Won Kim from UCSF. The complex and rapidly evolving treatment landscape for advanced RCC poses challenges for healthcare providers, particularly those in community settings, to make treatment decis...
|
- Details
- (Length of Discussion: 5 min) Dr. Thomas Keane reviews the IMmotion 151 Trial, a randomized Phase III Study of Atezolizumab Plus Bevacizumab versus Sunitinib in Untreated Metastatic Renal Cell Carcinoma. A topic presented by Robert J. Motzer, MD at the 2018 ASCO GU 2018 meeting. In this oral abstract session, Dr. Motzer presented the first phase III randomized clinical trial combining a PD-L1/PD-1...
|
- Details
- (Length of Discussion: 4 min) Dr. Thomas Keane reviews the Subgroup Analysis of Progression-free Survival and Objective Response Rate in the Alliance AO31203 CABOSUN trial for Advanced Renal Carcinoma presentation by Dr. Daniel George at the ASCO GU 2018 meeting. Cabozantinib, a small molecule designed to target the MET and ALK pathways in addition to VEGFR2 pathway has been shown to be superior t...
|
- Details
- (Length of Discussion: 34 min) Dr. Thomas Guzzo starts his discussion by dialing back to 1997 to share with listeners the beginning of Enhanced Recovery After Surgery (ERAS) and the work of Dr. Kelhlet from Denmark who described multifactorial surgical stress responses such as the pathogenesis of postoperative sleep disturbances as multifactorial, and includes different neural stimulus (surgical s...
|
- Details
- (Length of Discussion: 4 min) Dr. Thomas Keane provides a commentary on the The FALCON Trial , the impact of 18F-fluciclovine PET/CT on clinical management choices for men with biochemically recurrent prostate cancer presented at the recent 2018 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium . Eugene Jueren Teoh, MBBS, MRCP from the University of Oxford presented t...
|
- Details
- (Length of Discussion: 7 min) Dr. Thomas Keane reviews the first presentation on the PROSPER study which was a much awaited presentation presented by Dr. Maha Hussain at the recent 2018 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium . Dr. Hussain started her presentation on PROSPER, a phase III randomized double-blind controlled trial, Safety and Efficacy Study of...
|
- Details
- (Length of Discussion 17 min) Dr. Thomas Keane reviews recent groundbreaking data presented at the 2018 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium focusing on the much awaiting results of the SPARTAN trial. Dr. Keane started by highlighting the SPARTAN Trial presentation by Dr. Eric Small. A Study of Apalutamide (ARN-509) in Men with Non-Metastatic Castration-r...
|
